SCHEMBL543436

SCHEMBL543436

CC(C)C[CH]c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 3/20 0.47
ALDH1A1 P00352 2/20 0.42
CYP2A6 P11509 1/20 0.42
TSHR P16473 1/20 0.36
MAOB P27338 1/20 0.36
AHR P35869 1/20 0.35
NPC1 O15118 1/20 0.35
MTOR P42345 1/20 0.35
TP53 P04637 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
MAPK1 P28482 1/20 0.35
CYP2C19 P33261 1/20 0.35
HSD17B10 Q99714 1/20 0.35
LMNA P02545 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
TAAR1 Q96RJ0 2/20 0.34
MAOA P21397 1/20 0.34
SLC6A2 P23975 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6320160 0.87 TYR (0.39) HTR2AALDH1A1CYP2A6
SCHEMBL17330729 0.81 HTR2A (0.44) HTR2AALDH1A1CYP2A6TSHRAHR
SCHEMBL6028571 0.81 HTR2A (0.44) HTR2AALDH1A1CYP2A6TSHRMAOB
SCHEMBL4351016 0.81 HTR2A (0.64) HTR2ACYP2A6MAOBCYP2D6TAAR1
SCHEMBL8166743 0.79 HTR2A (0.42) HTR2AALDH1A1CYP2A6TSHRNPC1
SCHEMBL14910878 0.79 TAAR1 (0.50) HTR2ATAAR1
SCHEMBL17004006 0.78 HTR2A (0.41) HTR2AALDH1A1CYP2A6TSHRMAOB
SCHEMBL555307 0.78 HTR2A (0.41) HTR2AMAOBSLC6A2SLC6A4SLC6A3
SCHEMBL28607954 0.78 HTR2A (0.41) HTR2AALDH1A1CYP2A6TSHRNPC1
SCHEMBL436098 0.76 HSD17B10 (0.46) ALDH1A1CYP2A6MAOBAHRNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 416 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2951179-B1 SPIRO-QUINAZOLINONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND CONDITIONS MERCK PATENT GMBH (DE) 2020-03-11 EP claimed
CN-109336887-A A kind of benzimidazole and chiral heterocycle class compound and its preparation method and application 中山大学 2019-02-15 CN claimed
US-9908824-B2 Methods for selectively hydrogenating benzene with supported organometallic catalysts and systems and methods for reducing benzene in gasoline using such catalysts UOP LLC (US) 2018-03-06 US claimed
US-9862657-B2 Methods for selectively hydrogenating substituted arenes with supported organometallic catalysts UOP LLC (US) 2018-01-09 US claimed
US-9708321-B2 Spiro-quinazolinone derivatives and their use as positive allosteric modulators of mGluR4 MERCK PATENT GMBH (DE) 2017-07-18 US claimed
CN-106243099-A A kind of method of the novel nitrogen-containing tridentate ligand synthesis of nickel catalysis 浙江大学 2016-12-21 CN claimed
US-20160159709-A1 METHODS FOR SELECTIVELY HYDROGENATING SUBSTITUTED ARENES WITH SUPPORTED ORGANOMETALLIC CATALYSTS NORTHWESTERN UNIVERSITY 2016-06-09 US claimed
US-20150361079-A1 Spiro-Quinazolinone Derivatives and their Use as Positive Allosteric Modulators of mGluR4 MERCK PATENT GMBH (DE) 2015-12-17 US claimed
EP-2951179-A1 SPIRO-QUINAZOLINONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND CONDITIONS Merck Patent GmbH (DE) 2015-12-09 EP claimed
US-9205071-B2 Arsenic compounds, their preparation methods and uses thereof CHANGZHOU HI-TECH DISTRICT MULTIPLE DIMENSION INDUSTRY TECHNOLOGY INSTITUTE CO., LTD. (CN) 2015-12-08 US claimed
EP-2880020-A1 ENZYME-ACTIVATING COMPOUNDS AND COMPOSITIONS The Board of Trustees of the University of Illinois (US) 2015-06-10 EP claimed
WO-2014117920-A1 SPIRO-QUINAZOLINONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND CONDITIONS MERCK PATENT GMBH (DE) 2014-08-07 WO claimed
WO-2014022858-A1 ENZYME-ACTIVATING COMPOUNDS AND COMPOSITIONS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2014-02-06 WO claimed
US-20120039995-A1 ARSENIC COMPOUNDS, THEIR PREPARATION METHODS AND USES THEREOF CHANGZHOU HI-TECH DISTRICT MULTIPLE DIMENSION INDUSTRY TECHNOLOGY INSTITUTE CO., LTD. (CN) 2012-02-16 US claimed
CN-101525497-A Pyrazoline pyridino-benzo coumarin fluorescent dye derivative and synthesis method and application thereof CHINESE ACAD TECH INST PHYSICS (CN) 2009-09-09 CN claimed
US-6617426-B1 Peptide analogs of given formula; useful in treating neurodegenerative, autoimmune, cognitive disorders, stroke and traumatic injury MERCK SHARP & DOHME CORP. 2003-09-09 US claimed
EP-0752622-A1 Acetal polymers useful in photosensitive compositions MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1997-01-08 EP claimed
US-5534381-A POLYMERS FOR LITHOGRAPHIC PRINTING PLATES MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1996-07-09 US claimed
US-4339448-A Imidazole-copper complex compounds and fungicides containing them BASF AKTIENGESELLSCHAFT (DE) 1982-07-13 US claimed
EP-0010723-B1 COPPER COMPLEXES OF IMIDAZOLE, THEIR PREPARATION AND FUNGICIDES CONTAINING THEM BASF Aktiengesellschaft (DE) 1981-07-29 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160159709-A1 METHODS FOR SELECTIVELY HYDROGENATING SUBSTITUTED ARENES WITH SUPPORTED ORGANOMETALLIC CATALYSTS HPSE, TST, STS HTR2A 1671/4885ALDH1A1 2652/4885CYP2A6 1067/4885
US-20120039995-A1 ARSENIC COMPOUNDS, THEIR PREPARATION METHODS AND USES THEREOF AS3MT, MCL1, MLLT3 HTR2A 4342/4885ALDH1A1 185/4885CYP2A6 316/4885
US-20150361079-A1 Spiro-Quinazolinone Derivatives and their Use as Positive Allosteric Modulators of mGluR4 GRM4, GRIA4, GRIK4 HTR2A 332/4885ALDH1A1 4174/4885CYP2A6 3625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.